View Older Stories View More Recent Stories

Jan 10, 2022 08:00AM Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
Jan 5, 2022 07:30AM Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
Dec 20, 2021 08:31AM Summit Therapeutics (SMMT) Announces Phase III Ri-CoDIFy Study Did Not Meet Endpoints
Dec 20, 2021 08:30AM Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection
Nov 15, 2021 08:30AM Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2021
Nov 3, 2021 08:33AM Summit Therapeutics (SMMT) Appoints Urte Gayko to its Board
Nov 3, 2021 08:30AM Summit Therapeutics Bolsters Its Board of Directors with Seasoned Regulatory & Clinical Research Executive Dr. Urte Gayko
Oct 8, 2021 08:32AM Summit Therapeutics (SMMT) Appoints Kenneth A. Clark to Its Board
Oct 8, 2021 08:30AM Summit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of Directors
Sep 30, 2021 09:00AM Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021
Aug 11, 2021 08:01AM Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2021
Aug 11, 2021 08:00AM Summit Therapeutics Provides Update on Ri-CoDIFy Trials
Jul 12, 2021 08:29AM Summit Therapeutics (SMMT) Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole
Jul 12, 2021 08:29AM Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole
Jul 1, 2021 08:00AM Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster
Jun 8, 2021 07:00AM Summit Therapeutics set to join Russell 3000® Index
Jun 3, 2021 08:00AM Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
May 18, 2021 07:08AM Summit Therapeutics (SMMT) Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae
May 18, 2021 07:00AM Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO
May 17, 2021 08:00AM Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021
May 6, 2021 08:00AM Summit Therapeutics Publishes Scientific Updates to Corporate Website
Mar 17, 2021 07:00AM Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020
Nov 23, 2020 07:00AM Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer
Nov 16, 2020 04:05PM Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2020
Sep 29, 2020 07:00AM Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2020
Sep 18, 2020 07:11AM Summit Announces Effectiveness of Scheme of Arrangement and Completion of Redomiciliation to Delaware, USA
Sep 17, 2020 07:00AM Summit Therapeutics Announces U.K. Court Approval of Scheme
Aug 19, 2020 04:01PM Summit Announces Results of Court Meeting and General Meeting
Jul 16, 2020 07:03AM Summit Therapeutics (SMMT) to Redomicile its Holding Company to the United States
Jul 16, 2020 07:00AM Summit Announces Intention to Redomicile its Holding Company to the United States
Jul 13, 2020 07:02AM Summit Therapeutics (SMMT) Reports Phase 2 Clinical Analyses of Gut Microbiome Health
Jul 13, 2020 07:00AM Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health
Jun 8, 2020 07:02AM Summit Therapeutics (SMMT) Appoints Michael Donaldson as Chief Financial Officer
Jun 8, 2020 07:00AM Summit Appoints Michael Donaldson as Chief Financial Officer
Jun 2, 2020 04:01PM Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020
Apr 30, 2020 07:00AM Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress
Apr 14, 2020 09:15AM Summit Therapeutics (SMMT) Appoints Robert W. Duggan as CEO
Apr 14, 2020 09:15AM Summit Appoints Robert W. Duggan as Chief Executive Officer
Feb 26, 2020 07:00AM Summit Appoints Robert W. Duggan as Executive Chairman
Feb 6, 2020 07:00AM Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma
Feb 6, 2020 07:00AM Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma
Feb 4, 2020 07:00AM Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference
Feb 4, 2020 07:00AM Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference
Jan 23, 2020 07:07AM Summit Therapeutics (SMMT) Reports BARDA Expands Ridinilazole Award by $8.8M to Include Additional NDA-Enabling Work
Jan 23, 2020 07:00AM Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work
Jan 7, 2020 07:00AM Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection
Dec 17, 2019 07:00AM Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019
Dec 16, 2019 09:15AM Notice of Q3 Results
Nov 6, 2019 07:00AM Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
Nov 4, 2019 07:00AM Summit Therapeutics Recognises C. difficile Awareness Month
View More Recent Stories View Older Stories